introduction cognitive-related disease alzheimer disease well-known markedly impair memory negatively affect daily activity according world health organization estimated million individual worldwide suffer dementia expected triple however date optimal therapeutic strategy yet established recent decade growing interest research development food health-promoting effect also known functional food contain different type molecule diverse physiological function including vitamin polyphenols lipid peptide among peptide one important widely studied functional food-derived material reportedly exhibiting various physiological effect including beneficial effect brain establishing potential effect essential determine whether candidate compound reach target brain region across blood–brain barrier bbb system well elucidate mechanism underlying physiological response bbb strictly regulates transport substance brain past decade several method including silico vitro situ vivo model established examine transport molecule across bbb ks-487 discovered ldl receptor-related protein lrp1 -binding mer cyclic peptide permeability demonstrated using vitro rat monkey bbb kit model however major limitation currently available vitro model fail comprehensively mimic native bbb given use plastic porous transwell membrane insert thus affording inconsistent result compared vivo experiment vivo evaluation bbb permeation performed liquid chromatography -mass spectrometry using homogenized microdialyzed brain tissue perfusion experiment visualization analysis using positron-emission tomography pet mass spectrometric imaging technique notably invasiveness microdialysis may disrupt bbb system resulting poorly reliable observation addition magnetic resonance imaging quantitative radioautography fluorescence pet visualization technique limitation term preparing fluorophore- radio-isotope-labeled target small molecule without altering physicochemical property hence qualitative quantitative assessment bbb permeability target molecule remain technically challenging date oral administered memory-improved peptide gly-thr-trp- carboxyl- tyr shown distributed mouse brain tissue using radioactive tracing technique however may difficult distinguish target peptide fragmented metabolized peptide previously successfully demonstrated gly-sar gly-pro tyr-pro intact bbb transportable dipeptides determined conducting situ mouse brain perfusion experiment furthermore matrix-assisted laser desorption ionization maldi -ms imaging used demonstrate interesting finding regarding brain tissue accumulation wherein tyr-pro confirmed accumulated parenchyma mouse brain particularly hippocampus cerebral cortex cerebellum hypothalamus striatum region long-term oral administration study assessing tyr-pro amyloid β-injected model mouse provided first evidence orally administered tyr-pro improve impaired cognitive deficit considering working long-term memory situ vivo finding indicate tyr-pro could developed orally effective functional food preventing cognitive impairment irrespective preference tyr-pro intake bioavailability remains elusive including entry circulating blood system brain without degradation present study aimed determine whether tyr-pro reach brain parenchyma intact form oral administration mouse according protocol shown fig confirm intact accumulation tyr-pro highly sensitive detection tyr-pro using lc-quadrupole time-of-flight qtof established using 3-aminopyridyl- -hydroxysuccinimidyl carbamate apds derivatization technique figure schematic overview animal experiment detection workflow graphic illustration workflow acquire mouse plasma brain tissue icr mouse orally administrated mg/kg tyr- pro plasma brain tissue collected min flow chart clarifying plasma brain tissue processing protocol plasma brain tissue applied solid phase extraction reacted apds analyzed lc-qtof/ms apds 3-aminopyridyl- -hydroxysuccinimidyl carbamate lc-qtof/ms liquid chromatography-quadrupole time-of-flight/mass spectroscopy full size image result apds derivatization-lc-qtof/ms performance tyr-pro detection exclude influence endogenous tyr-pro mouse orally administered stable isotope-labeled tyr- pro tyr-pro used internal standard lc-qtof/ms measurement apds employed amine derivatization reagent given expected high ionization efficiency derivative lc–ms/ms current study apds-amine derivatization two isotope-labeled peptide performed apds 8.8 min fig considering reaction observed product monoisotopic precursor ion 405.1800 m/z tyr- pro attached apds moiety tyr-pro 409.1920 m/z quantitative selective detection two labeled dipeptides essential confirm whether apds derivatization applicable lc–ms detection target dipeptides plasma brain sample without interference sample matrix accordingly measured two labeled tyr-pro target help selected reaction monitoring srm analysis monitoring ion tyr- pro 405.1800 285.1480 m/z tyr-pro 409.1920 289.1600 m/z fig table based srm analysis observed highly selective non-interfering peak apds-tyr- pro along marked enhancement detection using apds derivatization factor approximately compared detection non-derivatized tyr- pro fig figure show matrix effect detection apds-tyr- pro mouse plasma brain homogenate spiked concentration pmol/ml-plasma fmol/mg-dry brain compared intensity apds-tyr- pro aqueous solution reduction intensity observed owing matrix effect plasma brain homogenate respectively thus quantification tyr- pro apds-aided srm-lc-qtof/ms analysis performed according calibration curve individually prepared plasma brain sample figure apds derivatization-lc-qtof/ms performance tyr-pro scheme apds derivatization reaction tyr-pro apds derivatization condition described material method section ms/ms infusion analysis apds-tyr- pro isotope-labeled atom highlighted red inserted structure highly sensitive dipeptide detection method based apds derivatization lc-qtof/ms extracted ion chromatogram intact tyr- pro 285.1480 0.005 m/z apds-derivatized tyr- pro 405.1800 285.1480 m/z srm-lc-qtof/ms analysis red arrow indicates peak target molecule matrix suppression effect detection apds-tyr- pro mouse plasma brain homogenate concentration tyr- pro spiked either standard solution water blank plasma blank brain homogenate optimized srm-lc-qtof/ms condition red arrow indicates peak target molecule full size image srm-lc-qtof/ms performance targeting dipeptide tyr-pro obtained good calibration curve apds-tyr- pro plasma brain sample aided addition tyr-pro pmol/ml-plasma 0.1 pmol/mg-dry brain calibration curve plasma calculated 0.0295x 0.0101 10–1500 pmol/ml-plasma 0.9891 peak area ratio observed peak area peptide peptide concentration pmol/ml-plasma considering brain sample calibration curve obtained 37.363x 0.0706 0.005–0.075 pmol/mg-dry brain 0.9954 peak area ratio peptide concentration dry brain tissue pmol/mg-dry brain based current srm-lc-qtof/ms least fmol/mg-dry brain tyr- pro achieved brain tissue presence target significantly detected based limit detection lod 9.99 pmol/ml-plasma 0.006 pmol/mg-dry brain plasma brain respectively well limit quantitation loq 30.3 pmol/ml-plasma 0.019 pmol/mg-dry brain plasma brain respectively table addition aforementioned good linearity calibration curve obtained using strongly indicated apds concentration employed present study sufficient appropriate derivatization target dipeptides even amine contaminant plasma sample matrix may affect apds derivatization efficiency absorption tyr-pro blood system oral administration icr mouse following oral administration tyr- pro mg/kg corresponding μmol/mouse respectively cardiac blood sampling performed establish absorption behavior circulating blood system apds-aided lc-qtof/ms analysis plasma sample obtained individual mouse min revealed presence intact tyr- pro plasma time post-administration fig help tyr-pro absorption kinetics tyr- pro mouse plasma evaluated max value pmol/ml-plasma max min 1/2 min area curve auc 0–120 min 10,424 pmol·min/ml-plasma mg/kg respectively fig table icr mouse orally administered tyr- pro mg/kg absorbed intact across intestinal membrane absorption ratio 0.15 0.03 1.46 0.29 nmol/whole plasma 0.10 0.04 11.5 4.5 nmol/whole plasma respectively figure absorption tyr-pro plasma oral administration icr mouse srm chromatogram lc–ms/ms analysis apds-tyr- pro blood single oral administration mouse representative srm chromatogram apds-tyr- pro 405.1800 285.1480 m/z plasma single oral administration mg/kg different time point 0–120 min shown corresponding chromatogram internal standard tyr-pro 409.1920 289.1800 m/z inserted small window chromatogram peak target molecule indicated arrow n.d. indicates detected plasma sample subjected apds derivatization followed lc–ms/ms-srm analysis described material method section time course plasma concentration tyr- pro single oral administration dos solid line mg/kg dotted line mouse value time point different dos calculated using present plasma calibration curve value expressed mean sem 3–5 full size image table pharmacokinetic parameter tyr- pro plasma oral administration icr mouse mg/kg full size table tyr-pro entry brain single oral administration icr mouse next aimed confirm entry tyr- pro brain tissue oral administration mg/kg icr mouse using present apds-lc-qtof/ms high sensitivity fmol/mg-dry brain lod shown fig significant detection tyr- pro observed min oral administration mg/kg-dosed mouse brain max value tyr- pro whole-brain tissue 0.009 0.004 0.089 0.044 pmol/mg-dry brain auc 0–120 min value 0.34 0.11 2.79 1.25 pmol·min/mg-dry brain mg/kg orally administrated dos respectively fig table surprisingly max tyr- pro brain tissue rapid min following rapidly decreased time 1/2 min mg/kg respectively table notably orally administered tyr- pro reached mouse brain tissue without degradation intact form percentage tyr- pro accumulated brain tissue 36.7 11.9 pmol/whole brain mg/kg 301.3 pmol/whole brain mg/kg 2.5 0.8 2.6 1.2 following total absorption tyr- pro mouse plasma dos 1.46 nmol/whole plasma mg/kg 11.5 nmol/whole plasma respectively figure reveals tyr- pro accumulated brain parenchyma brain microvessels suggesting observed brain accumulation fig table caused intact transport across bbb mouse figure entry tyr-pro brain single oral administration icr mouse srm chromatogram lc–ms/ms analysis apds-tyr- pro brain tissue single oral administration mouse representative srm chromatogram apds-tyr- pro 405.1800 285.1480 m/z brain tissue oral administration mg/kg different time point 0–120 min shown corresponding chromatogram internal standard tyr-pro 409.1920 289.1800 m/z inserted small window chromatogram peak target molecule indicated arrow n.d. indicates detected brain sample also subjected apds derivatization followed lc–ms/ms-srm analysis described material method section time course brain concentration tyr- pro single oral administration dos solid line mg/kg dotted line mouse value time point different dos calculated using present brain calibration curve value expressed mean sem 3–5 full size image table pharmacokinetics parameter tyr- pro brain oral administration icr mouse mg/kg full size table figure srm chromatogram lc–ms/ms analysis apds-tyr- pro parenchyma microvessel fraction min mg/kg oral administration icr mouse representative srm chromatogram apds-tyr- pro 405.1800 285.1480 m/z parenchyma microvessel min single oral administration mg/kg corresponding chromatogram internal standard tyr-pro 409.1920 289.1800 m/z inserted small window chromatogram peak target molecule indicated arrow n.d. indicates detected brain sample also subjected apds derivatization followed lc–ms/ms-srm analysis described material method section full size image local accumulation tyr-pro different brain region icr mouse given preferable accumulation tyr- pro brain parenchyma icr mouse following oral administration examined local accumulation relevant region apds-lc-qtof/ms previously reported tyr-pro mouse perfusion experiment accumulate hippocampus hypothalamus cerebral cortex striatum cerebellum brain tissue min oral administration tyr-pro mg/kg used local accumulation experiment low lod limited weight organ tissue shown fig significant accumulation administered tyr- pro detected hypothalamus 0.35 0.28 pmol/mg-dry tissue well hippocampus 0.03 0.01 pmol/mg-dry tissue cortex region 0.02 0.01 pmol/mg-dry tissue fig peak observed control group fig notably preferable local accumulation three region accounted whole-brain accumulation fig figure accumulation tyr- pro different brain region min mg/kg oral administration icr mouse distribution tyr- pro different brain region value calculated using brain calibration curve value expressed mean sem weight brain region shown brain tissue diagram white letter percentage total amount tyr- pro brain region total amount tyr- pro brain region calculated according average content multiplied tissue weight full size image discussion food-derived peptide class molecule multiple physiological function tissue fluid living organism date several peptide ppknw ypldlf gyypt vhvv mkp nippltqtpvvvppflqpe reported potentially improve impaired memory reduce risk age-related disease however although molecule shown vivo beneficial effect brain function ability reach brain system intact form yet discussed given peptide might undergo hydrolysis absorption restrict intact transport across bbb using present apds-aided lc-qtof/ms capable highly sensitive detection tyr-pro brain tissue fmol/mg-dry brain tissue aimed establish entry intact tyr-pro shown cross bbb mouse perfusion study brain system oral administration shown fig first report orally administered tyr-pro tyr- pro reached brain intact form early min post-administration finding strongly indicates memory-improving tyr-pro stably crossed intestinal membrane absorbed blood circulation immediately reached brain parenchyma male mouse fig however considering report sex difference may affect pharmacokinetics target mouse animal experiment using female mouse must needed clarify bioavailability tyr-pro mouse best knowledge first evidence highlighting intact transport peptide mouth brain noteworthy peptide exhibit physiological potential orally active memory-improving food compound observed 15-min max tyr- pro icr mouse blood circulation post-oral administration table rapid compared reported absorption kinetics dipeptides e.g. max trp-his min max val-tyr min rapid absorption tyr-pro blood system might attributed high affinity pept1 transporter similar hydroxypro-containing peptide kinetic study concerning max using vitro transport experiment caco-2 cell monolayers ongoing kinetic study also elucidate mechanism underlying marked absorption magnitude tyr-pro auc 0–120 min pmol·min/ml-plasma mg/kg table compared reported absorbable dipeptides trp-his auc 0-6 71.3 18.7 pmol·h/ml-plasma mg/kg oral administration val-tyr auc 0–6 19.4 0.71 pmol·h/ml-plasma mg/kg oral administration rapid accumulation tyr- pro icr mouse brain system min oral administration table could explained rapid transport dipeptide 0.5 min post-perfusion previous report although bbb transport route including l-type amino acid transporter lat1 peptide histidine transporter pht2 tyr-pro remain uncertain rapid transport tyr-pro comparable drug examined mouse perfusion study including nicotine 0.5 min quinine 0.25 min acetaminophen also shown rapidly accumulate brain early min oral administration mg/kg thereby strongly supporting present result according report ayoub penetration power brain/plasma accumulation ratio anti-diabetic drug omarigliptin 0.23 tyr-pro 0.036 1.8 pmol/g-wet brain/49 pmol/ml-plasma min table may 1/6-fold lower penetration power compared omarigliptin transportability compound brain system strictly regulated bbb currently report established entry bioactive peptide across bbb oral administration herein demonstrated significant accumulation tyr- pro mouse brain parenchyma auc 0–120 min 0.34 0.11 2.79 1.25 pmol·min/mg-dry brain oral dos mg/kg respectively table accumulation tyr-pro 0.0037 mg/kg 0.0027 mg/kg oral dose markedly low achieve effective acute action compared drug compound courad reported acetaminophen known exhibit analgesic effect via central nervous system cns reached brain accumulation 0.1 oral dose mg/kg another report claimed morphine brain accumulation 0.01 oral dose mg/kg considering brain-transportable natural compound 1-deoxynojirimycin showed appropriate accumulation 1.2 pmol/mg brain sprague–dawley rat oral administration μmol 6.5 mg/kg conversely despite low accumulation poor uptake ratio 0.0037 tyr- pro mouse brain mg/kg observed present oral administration study previously shown significant improvement impaired memory amyloid β-induced mouse following daily tyr-pro intake mg/kg twice day day suggesting low tyr-pro accumulation even mg/kg would effective one expects preventive effect onset present study demonstrated preferable accumulation orally administrated tyr-pro cortex hippocampus hypothalamus fig fig region tyr-pro accumulation good agreement region visualized maldi-ms imaging mouse perfusion experiment tyr-pro hypothalamus regulates body temperature sleep pattern control hunger thirst play role memory emotional action hippocampus cortex may involved memory learning navigation perception space thus speculated based previous report brain health benefit tyr-pro local accumulation aforementioned region long-term administration study tyr-pro currently progress preventive mechanism effective dose tyr-pro oral intake remain unclear date acetylcholinesterase ache inhibitor donepezil developed suppress reduction neurotransmitter factor ach contrast tyr-pro accumulation brain reportedly induces upregulation choline acetyltransferase chat expression thereby promoting ach production although action tyr-pro brain differs drug regulation cholinergic nervous system appropriate target prevention via peptide intake mechanism underlying upstream signaling cascade chat activation via tyr-pro currently investigation using ne-4c neural stem cell-line experiment conclusion provided novel finding intact tyr-pro reach brain oral administration icr mouse detection tyr-pro i.e. min oral administration strongly indicates transport blood brain across bbb rapid following entry blood circulation apds derivatization-aided lc-qtof/ms method also demonstrated accumulation tyr-pro brain tissue 0.02 pmol/mg-dry brain particular cortex hippocampus hypothalamus transport ratio 2.6 total absorption blood circulation 0.0027 mg/kg administered dose material method chemical reagent tyr- pro lot sq21192 sq23862 sq25025 tyr-pro lot sq25407 synthesized scrum co. tokyo japan apds lot efj0223 dgg0331 purchased fujifilm wako co. osaka japan distilled water methanol meoh acetonitrile acn formic acid lc–ms grade merck darmstadt germany reagent used present study analytical grade used without purification animal experiment present study performed using seven- nine-week-old male icr mouse weighing 25–35 jcl icr clea japan tokyo japan mouse housed one week controlled temperature humidity h-light–dark cycle 8:00 8:00 mouse fed laboratory diet ce-2 clea japan provided water libitum mouse fasted prior oral administration tyr- pro animal experiment conducted accordance proper conduct animal experiment related activity academic research institution jurisdiction ministry education culture sport science technology japan method reported accordance arrive guideline ethic committee animal experiment fukuoka university approved experimental protocol permit number administration experiment experimentation day mouse randomly divided three group control group mg/kg tyr- pro group mg/kg tyr- pro group control group administered water two group administered mg/kg tyr- pro dissolved water blood brain collected mouse min post-administration 3–5 scheduled time blood collected left ventricle heart anesthesia urethane sigma-aldrich st. louis usa placed 1.5 tube containing ethylenediaminetetraacetic acid disodium salt edta-2na mg/tube whole brain harvested according following procedure briefly descending thoracic aorta ligated left jugular aorta sectioned perfused freshly prepared physiological buffer nacl kcl 2.8 cacl mgso ∙7h nah ∙2h -glucose hepes 7.4 wash blood brain perfusion physiological buffer whole brain removed mouse decapitation subsequently weighed blood sample centrifuged min obtain plasma specimen followed storage -30 lc-qtof/ms analysis brain sample wet weight 0.5 g/mouse immediately frozen liquid nitrogen following lyophilization lyophilized brain sample dry weight 0.1 g/mouse stored analysis determine tyr- pro local region brain separate administration study performed examining hypothalamus 1.6 0.2 hippocampus 7.3 0.2 cortex 33.4 0.3 organ 58.5 2.0 three mouse min post-administration mg/kg tyr- pro lyophilization sample stored analysis preparation brain parenchyma microvessel fraction parenchyma microvessel fraction separated mouse brain min tyr- pro administration mg/kg according previous report separate administration experiment brain sample mouse minced using glass homogenizer physiological buffer 0.5 followed homogenization adding 1.0 26.5 dextran homogenate obtained centrifuged min supernatant representing parenchymal fraction pellet representing microvessel fraction carefully collected subsequently physiological buffer added supernatant centrifuged min obtain brain parenchyma considering pellet 1.5 17.7 dextran added pellet followed centrifugation min obtain microvessel fraction parenchyma microvessel fraction frozen stored analysis lc-qtof/ms analysis combined apds derivatization technique determining tyr- pro plasma determine plasma tyr- pro plasma aliquot mixed 0.1 triton x-100 solution containing 0.1 following addition 0.1 μmol/l tyr-pro solution thoroughly mixed vortexing loaded onto sep-pak vac c18 cartridge water co. milford usa pre-conditioned sequentially meoh containing 0.1 0.1 cartridge washed 0.1 eluted meoh containing 0.1 1.0 ml/min eluent evaporated dryness dissolved borate buffer adding apds solution acn apds derivatization reaction initiated min thereafter apds reaction stopped adding 0.1 solution aliquot solution filtered millex-lg syringe filter millipore co. carrigtwohill ireland subjected lc-qtof/ms analysis calibration curve tyr- pro mouse plasma obtained spiking different concentration tyr- pro final concentration 10–1500 pmol/ml-plasma along 0.1 μmol/l tyr-pro pmol/ml-plasma blank plasma intensity ratio observed peak area peptide used establish calibration curve lod loq tyr- pro determined 3.3 standard deviation sd/slope respectively system comprised agilent series hplc system agilent technology waldbronn germany separation conducted 5c18-ar-ii 2.0 i.d particle size nacalai tesque co. kyoto japan gradient elution flow rate 0.25 ml/min solution 0.1 water solution 0.1 meoh gradient condition 0–100 solution min qtof/ms analysis performed using compact bruker daltonics bremen germany electrospray ionization esi -positive ion mode srm measurement set follows drying gas 8.0 l/min drying temperature nebulizer pressure 2.0 bar capillary end plate offset mass range 50–1000 m/z monoisotopic isolation m/z molecular ion selection width 405.1800 285.1480 409.1920 289.1600 tyr- pro tyr-pro respectively cone voltage set collision energy set tyr- pro tyr-pro respectively calibration solution sodium formate acn injected beginning run spectrum calibrated internally data analyzed using bruker data analysis software ver 3.2 srm chromatogram width 0.005 m/z lc-qtof/ms analysis combined apds derivatization technique determining tyr- pro brain lyophilized brain sample pounded using biomasher nippi inc tokyo japan 2.9 0.1 triton x-100 solution containing 0.1 0.1 nmol/l tyr-pro 0.1 pmol/mg-dry brain added aliquot brain powder solution homogenized using polytron homogenizer kinematica luzern switzerland 20,000 rpm twice followed sonication using sonifire branson ultrasonics emerson japan co. kanagawa japan output control performed three time prepared sample centrifuged min supernatant subjected sep-pak vac c18 cartridge water co. followed apds derivatization lc-qtof/ms analysis briefly cartridge pre-conditioned sequentially meoh containing 0.1 0.1 washed 0.1 eluted meoh containing 0.1 1.0 ml/min eluent evaporated dryness applied apds derivatization described aforementioned protocol calibration curve tyr- pro mouse brain obtained spiking different concentration tyr- pro final concentration 0.005–0.075 pmol/mg-dry brain respectively along nmol/l tyr-pro 0.1 pmol/mg-dry brain blank brain homogenate data analysis concentration–time pharmacokinetic data analyzed using graphpad prism software ver 9.4.0 graphpad jolla max max auc 0–120 min value obtained measuring accumulated target substance observation period 1/2 value obtained using equation 0.693/k elimination rate constant determined linear regression analysis data point plotted max min absorption ratio tyr-pro plasma brain obtained dividing auc 0–120 min whole plasma volume 1.1 ml/mouse auc 0–120 min whole dry brain weight mg/mouse oral dose respectively result expressed mean standard error mean sem